HT1005
Sodium Thiosulfate Solution
2 g/dL in deionized water
Synonym(s):
Sodium thiosulfate solution
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
Na2S2O3
CAS Number:
Molecular Weight:
158.11
NACRES:
NA.47
PubChem Substance ID:
UNSPSC Code:
12352302
MDL number:
description
For use in the Silver Stain Kit No. HT100-A
Quality Level
form
solution
shelf life
Expiry date on the label
IVD
for in vitro diagnostic use
concentration
2 g/dL in deionized water
application(s)
hematology
histology
storage temp.
2-8°C
SMILES string
[Na+].[Na+].[O-]S([O-])(=O)=S
InChI
1S/2Na.H2O3S2/c;;1-5(2,3)4/h;;(H2,1,2,3,4)/q2*+1;/p-2
InChI key
AKHNMLFCWUSKQB-UHFFFAOYSA-L
Application
For use in the Silver Stain Kit No. HT100-A
Still not finding the right product?
Explore all of our products under Sodium Thiosulfate Solution
Storage Class
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
S Van Haute et al.
International journal of food microbiology, 208, 102-113 (2015-06-13)
A methodology to i) assess the feasibility of water disinfection in fresh-cut leafy greens wash water and ii) to compare the disinfectant efficiency of water disinfectants was defined and applied for a combination of peracetic acid (PAA) and lactic acid
Melvin R Hayden et al.
Cardiovascular diabetology, 4, 4-4 (2005-03-22)
Vascular calcification is associated with metabolic syndrome, diabetes, hypertension, atherosclerosis, chronic kidney disease, and end stage renal disease. Each of the above contributes to an accelerated and premature demise primarily due to cardiovascular disease. The above conditions are associated with
D R Gandara et al.
Critical reviews in oncology/hematology, 10(4), 353-365 (1990-01-01)
Cisplatin has a steep dose response curve for both antitumor and adverse effects. Therapeutic strategies aimed at reducing toxicity and allowing dose escalation of intravenous cisplatin, such as administration in hypertonic saline and pharmacokinetically based dosing schedules, have been partially